reversed-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Dissolution is normally performed in water, phosphate-buffered saline, or normal saline, since the peptide is freely soluble in aqueous media and is rarely handled with strong organic solvents. Solution pH should be kept near neutral, because extreme acidity or alkalinity accelerates backbone hydrolysis and encourages oxidation of the methionine side chain. Once dissolved, the material is less stable than the dry powder and is commonly divided into single-use portions and frozen. Buffers containing primary amines, such as Tris, are often avoided because of possible side reactions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its chain combines the first seven residues of corticotropin with a C-terminal proline-glycine-proline extension, a modification intended to slow enzymatic breakdown. The free peptide has a molecular mass near 813.9 daltons. It belongs to the class of ACTH-derived fragments studied for central nervous system activity rather than for adrenal steroid stimulation. This structural relationship to a natural hormone fragment is the usual starting point for describing the compound in the literature.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
== History == Van Gieson’s stain was first described by Ira T. Van Gieson in 1889 as a method for examining nervous system tissue. Van Gieson was a pathologist who published The Laboratory notes of technical methods for the nervous system in 1889, introducing the picric–fuchsin method at that time. In early 20th century the stain was combined with other techniques. In 1908, Friedrich hermann verhoeff introduced an iron–hematoxylin stain for elastic fibers, which used with Van Gieson’s counterstain to form the Verhoeff–Van Gieson (VVG) stain. In VVG staining, elastic fibers are stained black (by Verhoeff’s hematoxylin), collagen appears red (by Van Gieson), and cytoplasm elements are yellow.
Initially, by analogy with neutron magic number 126, the next proton shell was also expected at element 126, too far beyond the synthesis capabilities of the mid-20th century to get much theoretical attention. In 1966, new values for the potential and spin–orbit interaction in this region of the periodic table contradicted this and predicted that the next proton shell would instead be at element 114, and that nuclei in this region would be relatively stable against spontaneous fission. The expected closed neutron shells in this region were at neutron number 184 or 196, making 298Fl and 310Fl candidates for being doubly magic. 1972 estimates predicted a half-life of around 1 year for 298Fl, which was expected to be near an island of stability centered near 294Ds (with a half-life around 1010 years, comparable to 232Th). After making the first isotopes of elements 112–118 at the turn of the 21st century, it was found that these neutron-deficient isotopes were stabilized against fission. In 2008 it was thus hypothesized that the stabilization against fission of these nuclides was due to their oblate nuclei, and that a region of oblate nuclei was centred on 288Fl. Also, new theoretical models showed that the expected energy gap between the proton orbitals 2f7/2 (filled at element 114) and 2f5/2 (filled at element 120) was smaller than expected, so element 114 no longer appeared to be a stable spherical closed nuclear shell.
From 1989, when Bush took office, to 1993, when he left, the number of black males in American prisons increased by 300,000 people. The number of white males increased by 50,000 inmates. The number of sentences for drugs increased from 25,309 in 1989 to 48,554 in 1993.
==== Joining the Colorado Party ==== Peña joined the conservative Colorado Party on 29 October 2016, having previously been a member of the Authentic Radical Liberal Party (PLRA) for 20 years since joining at the age of 17. Peña's membership in the Colorado Party caused controversy, with reports that he only joined the party after Horacio Cartes announced his intention to dismiss members of his cabinet who were not party members. Peña released a statement stating he had joined the party due to its focus on developing Paraguay, and claimed to be the descendent of one of the party's founders, Jaime Peña. Following this, an electoral court annulled Peña's membership to the PLRA.
== Epidemiology == About 1 in 4,000 children in the United States will develop mitochondrial disease by the age of 10 years. Up to 4,000 children per year in the US are born with a type of mitochondrial disease. Because mitochondrial disorders contain many variations and subsets, some particular mitochondrial disorders are very rare. The average number of births per year among women at risk for transmitting mtDNA disease is estimated to approximately 150 in the United Kingdom and 800 in the United States.
Sources: en.wikipedia.org
Jaquelyn Patricia Longworth, Operational Safety and Policy Manager, Nuclear Electric Ltd. For services to Engineering Management. Walter Herbert Love. For services to Radio Journalism. Maurice Ernest Lowe, Engineering Manager, Vosper Thornycroft (UK) Ltd. For services to the Defence Industry. William Lowe. For services to the Library Service. June Valerie Lucas. For services to the community in Stanford Rivers, Essex. Brenda Germaine Lynn, Sub Divisional Officer, Special Constabulary, West Yorkshire Police. For services to the Police. Monica Lynskey, lately Administrative Officer, Office for Standards in Education. James Archibald MacDonald, Head Greenkeeper, Royal Lytham & St Annes Golf Club. For services to Golf. Thomas MacDougall, Retained Sub-Officer, Tayside Fire Brigade. For services to the Fire Service. Williamina MacGregor, School Cook, Lochardil Primary School, Inverness. For services to Education. Jean Macinnes. For services to the Citizens' Advice Bureau in Aberdeen. Laurence Macintyre, Chief Superintendent, Strathclyde Police. For services to the Police. John Kenneth MacKay, Crofter. For services to the community in Sutherlandshire. John Watson Mackay, Head of Recreation and Access Branch, Research and Advisory Services, Directorate, Scottish Natural Heritage. For services to Countryside Recreation. Florence King MacKenzie, Director, Scottish Churches Architectural Heritage Trust. For services to the Restoration of Church Buildings. George MacLean, lately Manager, Air Traffic Service, Sumburgh Airport (Shetland), Civil Aviation Authority.
The Indian Council of Historical Research (ICHR) is an autonomous body of the Ministry of Education, Government of India established by an Administrative Order. The body has provided financial assistance to historians and scholars through fellowships, grants, and symposia. The ICHR receives grants-in-aid from the Department of Higher Education, grants-in-aid from various Indian states, private donations, and the proceeds of revenues from the sale of publications of the ICHR. The ICHR is based in Delhi, with regional centres in Pune (Maharashtra), Bengaluru (Karnataka), and Guwahati (Assam). It was established on 27 March 1972. Its first chairman was the historian Ram Sharan Sharma. Historians who have served as members or functionaries of the ICHR include Irfan Habib, Tapan Raychaudhuri, and Barun De.
=== Dextran conjugate nanoparticles === Dextran conjugates are also utilized in nanoparticle drug delivery system formulations. Nanoparticles composted of dextran and stearic acid with a polyethylene glycol (PEG) coating can be loaded with antiviral drugs and be effectively internalized by cells. This nanosystem has the advantages of providing protection against immune responses and providing stability to the encapsulated drug. This technology has applications in the treatment of HIV and AIDS. Dextran can be grafted with folic acid to develop doxorubicin-loaded nanoparticles. Dextran-folic acid nanoparticles effectively target tumors, reduce off-site toxicity, and prolong blood circulation. Dextran-spermine nanoparticles loaded with doxorubicin can achieve targeted and sustained drug release in tumors.
On 4 January 2023, it was reported that Brazil was seeking an Amazon summit between members of the Amazon Cooperation Treaty Organization (ACTO) and other non-members, which was reportedly well received by the ACTO countries. On 26 January, Lula invited French president Emmanuel Macron to attend the ACTO summit due to the French department of French Guiana location in the Amazon region.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
Dry powder is usually kept at about -20 degrees Celsius for long-term storage and at 2 to 8 degrees Celsius for short working periods. Containers should stay sealed and protected from light and moisture to limit degradation.